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Accumulation of alpha-synuclein (α-syn) in Lewy bodies and neurites of midbrain
dopamine neurons is diagnostic for Parkinson’s disease (PD), leading to the proposal
that PD is a toxic gain-of-function synucleinopathy. Here we discuss the alternative
viewpoint that α-syn displacement from synapses by misfolding and aggregation results
in a toxic loss-of-function. In support of this hypothesis we provide evidence from our
pilot study demonstrating that knockdown of endogenous α-syn in dopamine neurons of
non-human primates reproduces the pattern of nigrostriatal degeneration characteristic
of PD.
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ALPHA-SYNUCLEIN IN PARKINSON’S DISEASE
The best-validated participant in the molecular pathology of Parkinson’s disease (PD) is alpha-
synuclein (α-syn). Mutations and multiplications of the α-syn SNCA gene locus both produce
inherited forms of PD (Polymeropoulos et al., 1997; Singleton et al., 2003; Ibanez et al., 2004). In
addition, the presence of α-syn in Lewy bodies and neurites of midbrain dopamine (DA) neurons,
the histological hallmark of PD, provides evidence for its association with idiopathic PD (Spillantini
et al., 1997). While a pervasive viewpoint postulates that excess α-syn and consequent aggregation
directly fuels neurotoxicity in a toxic gain-of-function event, it also is acknowledged that α-syn
aggregation may endanger neurons by removing the protein from its normal cellular location and
diminishing its function in a toxic loss-of-function event (Perez andHastings, 2004; Cookson, 2006;
Kanaan and Manfredsson, 2012). This issue remains a topic of debate.
Despite this ambiguity, approaches that may indiscriminately reduce α-syn in the central
nervous system represent an active area of research as an approach for treating PD (e.g., AFFiRiS
PD01, Prothena/Roche PRX002). In this Hypothesis and Theory article, we discuss evidence from
rodent and non-human primate experiments suggesting that Parkinson’s-like degeneration of the
nigrostriatal DA system can be reproduced by eliminating endogenous α-syn from DA neurons
vulnerable to degeneration in PD. These studies support the tentative conclusion that α-syn
elimination therapies that do not distinguish between native and abnormal forms may compromise
the viability of DA neurons and should proceed with caution.
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KNOCKDOWN OF α-SYN IN THE ADULT
RAT RESULTS IN DOSE-DEPENDENT
NIGROSTRIATAL DEGENERATION
The lack of overt pathology in α-syn germ-line knockout
animals (Abeliovich et al., 2000) and the commonly proposed
toxic gain-of-function of the α-syn mutant versions (A53T,
A30P, E46K; Kruger et al., 1998; Giasson et al., 2002; Klein
et al., 2002; Zarranz et al., 2004) led many investigators, us
among them, to pursue targeted knockdown of α-syn expression
as a potential therapeutic avenue for PD. However, using
recombinant adeno-associated virus (rAAV) expressing a short
hairpin RNA (shRNA) to knock down α-syn in mature rat
substantia nigra (SN) DA neurons we encountered a surprising
result: DA neuron degeneration (Gorbatyuk et al., 2010). In
our rodent studies, neurodegeneration could be rescued by co-
expression of rat α-syn (rendered insensitive to the shRNA)
demonstrating that neuronal loss was explicitly due to a toxic
loss-of function of α-syn and not due to non-specific shRNA-
mediated toxicity. Moreover, by utilizing several distinct shRNA
sequences displaying varying efficiencies of endogenous rat α-syn
mRNA knockdown we showed that the extent of neuronal loss
was dependent on the level of remaining α-syn. The ability
to rescue neurons by co-expression of rat α-syn and the fact
that toxicity was proportional to the efficiencies of shRNAs
demonstrate that neuronal loss was not due to “off-targeting” of
other endogenousmRNAs or due to non-specific shRNA toxicity.
KNOCKDOWN OF α-SYN IN THE
NON-HUMAN PRIMATE RESULTS IN
DOSE-DEPENDENT NIGROSTRIATAL
DEGENERATION: A CASE STUDY
To begin to further characterize the consequences of knockdown
of endogenous α-syn and determine whether effects seen in rats
were reproducible in a species more closely related to humans, we
generated an α-syn shRNA specific for St.Kitts green monkeys
(Chlorocebus sabaeus). We injected α-syn shRNA or scrambled
shRNA, of two different titers, into the SN of individual
monkeys (N = 4 total), waited 3 months, and examined
DA neuron numbers, morphology, striatal innervation, and
striatal DA content. α-Syn shRNA produced region-specific,
titer-related, degeneration of SN tyrosine hydroxylase-positive
(TH+) neurons and innervation of the striatum, reproducing
the pattern of nigrostriatal degeneration observed in PD: SN
degeneration was exaggerated in ventral tier neurons (vtSN;
Gibb and Lees, 1991) with relative sparing of adjacent ventral
tegmental area (VTA) DA neurons, and loss of TH+ fibers in the
putamen (Pt) exceeded denervation of the caudate nucleus (Cd)
(Kish et al., 1988; Figure 1). Stereologic quantification of TH+
neurons confirmed the qualitative observations: loss of TH+
neurons was greatest in vtSN with the VTA exhibiting relatively
little neuron loss. However, the general pattern of TH+ neuron
loss was not different in the High and Low titer α-syn shRNA
conditions. These neurons also contain neuromelanin, and when
counts of neuromelanin-only positive cells were added to the
analysis, titer-related differences emerged. The Low titer shRNA
condition was associated with the preservation of significantly
more neuromelanin-only neurons, suggesting that while loss
of TH+ phenotype was equivalent across titers, overt loss of
neurons was greater in the High titer condition. The presence
of TH-negative, neuromelanin-positive neurons is suggestive of
ongoing pathology, an observation that also is seen in early PD.
Importantly, co-localization of green fluorescent protein (GFP)
as a marker of viral transduction within surviving midbrain
DA neurons confirmed that dorsal SN and VTA neurons were
transduced, but showed less degeneration (Figure 1). Titer-
related differences in striatal DA depletion also were detected.
Deficits in DA in the caudate nucleus and putamen were
exaggerated in the α-syn shRNA High titer condition and a
significant increase in the homovanillic acid (HVA)/DA ratio was
only detected in the High titer subject. Increase in the HVA/DA
ratio is known to be associated with a compensatory response to
ongoing significant degeneration of DA neurons (Zigmond et al.,
1990).
HOW DOES LOSS OF PRESYNAPTIC
α-SYN CONTRIBUTE TO
NEURODEGENERATION?
The scope of our one subject per treatment condition pilot study
in non-human primates has clear limitations. Nevertheless, the
results confirm our previous findings in the rat (Gorbatyuk et al.,
2010; Kanaan andManfredsson, 2012). At this stage our findings,
while internally consistent among the treatment conditions, must
be considered as generating a hypothesis, rather than being
conclusive. While the idea that maintaining α-syn expression is
critical for survival of populations of adult neurons has received
relatively little investigation, the high prevalence and widespread
distribution of α-syn in brain inarguably reflects an important
function in synapses. While direct evidence for the loss-of-
function hypothesis is in its early stages, many studies provide
indirect support for the concept.
Alpha-synuclein exhibits a dramatic redistribution within the
neuronal compartment as a function of aging: the best-validated
primary risk factor for PD. A quantitative morphological
postmortem analysis of α-syn immunoreactivity within SN
DA neurons of humans reveals a distinct pattern of increased
staining within neuronal soma with advancing chronological age
(Chu and Kordower, 2007). Samples were from individuals with
a mean age of 31 years (young group, N = 6), 55 years (middle-
aged, N = 4) and 84 years (aged, N = 8). Alpha-synuclein
immunoreactivity was rarely detected in the soma of SN neurons
in young individuals and was restricted to its normal location
in the neuropil. With advancing age, a progressive increase
in somatic immunoreactivity was observed, culminating in a
639% increase in aged subjects. Quantitation of the intensity of
somatic staining on a per neuron basis confirmed this pattern,
illustrating a mean 57% increase in aged subjects as compared
to young. It is noteworthy that none of these samples exhibited
α-syn aggregates, suggesting that this intracellular redistribution
of α-syn may be an ongoing aging-related event that precedes
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FIGURE 1 | Knock-down of endogenous α-syn in midbrain dopamine neurons reproduces a PD-like pattern of nigrostriatal degeneration. rAAV-
α-syn-shRNA treatment produces exaggerated degeneration of ventral tier substantia nigra (vtSN) dopamine neurons and denervation of the putamen (Pt) that
exceeds that in the caudate (Cd), reproducing the pattern of degeneration observed in Parkinson’s disease [A,B,E,G,H, transduced hemisphere on right side of
micrographs, staining for tyrosine hydroxylase (TH)]. This pattern is not observed with rAAV-scr-shRNA treatment (C,D,F,I,J, arrows in (J) indicate injection site).
Dorsal tier substantia nigra (dtSN) neurons surviving α-syn-shRNA treatment (white asterisk in H) were transduced by the vector, but resistant to degeneration (K,
brown stain for GFP vector tag). While rAAV- α-syn-shRNA of both High and Low titers produced equivalent loss of TH+ vtSN neurons, greater numbers of
neuromelanin-positive neurons surviving in this region following Low titer treatment (M) indicates phenotype suppression with cell survival, and the low number of
these cells in the High titer treatment (L) suggests greater overt cell loss [black asterisk in (H) indicates vtSN region shown in (L) and equivalent region in (M) with
greater (Low shRNA titer M) and lesser (High titer in L) numbers of surviving neuromelanin neurons (brown pigment)]. Abbreviations: Cd, caudate nucleus; Pt,
putamen; ic, internal capsule; dtSN, dorsal tier substantia nigra; vtSN, ventral tier substantia nigra; Calibration bar in (A) = 100µm and applies to (A–F); bar in (G) =
500µm and applies to (G–J); bar in (M) = 100µm and applies to (K–L).
processes of aggregation. The same pattern was observed in aging
monkeys. Of importance to the loss-of-function hypothesis,
no comparison to α-syn distribution/levels in striatum was
performed, providing no opportunity to assess whether
increased somatic levels are associated with decreased synaptic
levels.
Oxidative stress is an established threat to DA neuron viability
and can be significantly exacerbated by DA mishandling
(i.e., increased cytosolic DA). Indeed, multiple lines of
evidence suggest a regulatory role for synuclein in dopamine
neurotransmission (Perez et al., 2002; Maries et al., 2003;
Wersinger et al., 2003), consistent with the view that loss of
presynaptic α-syn may contribute to increased oxidative stress
via dysregulation of DA biosynthesis, release and metabolism.
Studies in primary cultures of DA neurons demonstrate that
in conditions of elevated oxidative stress, endogenous levels of
α-syn increase and provide neuroprotection (Quilty et al., 2006;
Musgrove et al., 2011). Similarly, transgenicmice over-expressing
α-syn are resistant to paraquat-induced toxicity for DA neurons
known to be associated with oxidative stress (Manning-Bog et al.,
2003). Thus, endogenous α-syn likely provides an important DA
neuron defense against oxidative damage.
Mishandling of synaptic DA and the toxic byproducts of its
metabolism in the cytosol have a long history of association
with the vulnerability of these neurons (e.g., Perez and Hastings,
2004; Segura-Aguilar et al., 2014). Studies of transgenic mice
deficient in α-syn, while free of overt DA neuron pathology in
adulthood, exhibit changes in DA neurotransmission, with some
of these becoming exaggerated in aged animals. Adult, triple
knock-out mice for all synuclein family proteins exhibit elevated
evoked release of DA in striatum, enhanced turnover and reduced
presynaptic DA stores (Anwar et al., 2011). Study of two α-syn
deficient mouse lines found evidence for increased stimulated
DA overflow in striatum, higher basal extracellular DA levels,
decreased expression of the dopamine transporter (DAT) and
reduced DA reuptake (Chadchankar et al., 2011). Aged (24–
26 months old) α-syn null mice exhibit significant reduction of
striatal DA, a decrease in TH+ fibers and decreased striatal levels
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of TH and DAT (Al-Wandi et al., 2010). These data support
the view that α-syn is a pivotal presynaptic regulator of DA
neurotransmission and that disruption of this process may result
in chronic accumulation of DA in the cytosol.
Perhaps themost direct evidence for an α-syn loss-of-function
process related to aggregation comes from the mouse pre-formed
fibril (PFF) model of synucleinopathy (Luk et al., 2012). In
this model, intracerebral injection of pre-formed fibrils of α-syn
seeds misfolding of endogenous α-syn, resulting in progressive
accumulation of cytoplasmic aggregates of the protein. In a recent
report (Osterberg et al., 2015) the formation of aggregates was
tracked over time. The findings indicate that as inclusions mature
into a compact form, detection of soluble α-syn shows a parallel
decline.
IS TOXICITY DUE TO LOSS OF α-SYN
RELEVANT TO PARKINSON’S DISEASE
ETIOLOGY?
Direct assessment of the relevance of the α-syn loss-of-function
hypothesis to PD is a challenge. At present, there is no imaging
protocol specific for α-syn, although this is an active area of
research. To the best of our knowledge, there has been no study of
striatal synaptosome preparations comparing PD to controls and
there may be significant technical limitations to this approach
with postmortem tissue. In addition, since numerous neuronal
circuits project to the striatum, it may be difficult to discern what
effect is directly attributable to nigrostriatal projections. Studies
of α-syn in body fluids as a biomarker for PDmay hold clues, but
often are difficult to interpret in the context of entry of α-syn into
these compartments and the potential presence or impairment of
mechanisms operating to maintain homeostasis. However, α-syn
is enriched in brain and blood, and from the context of PD as a
“whole body” syndrome it can be argued that a systemic change
in α-syn that characterizes PD may be detectable in blood as a
reflection of a general process that affects brain. Taken together,
biomarker studies targeting α-syn present a set of mixed results
(Malek et al., 2014 for review), documenting increases, decreases
and no differences in PD subjects as compared to controls. Many
of these conclusions likely are linked to differences in sample
collection, preparation and the assay employed. One recent
report takes a different approach to circumvent the complexities
of accurately measuring α-syn protein in blood and measured α-
syn transcripts. They analyzed blood samples from three large
cohorts of PD patients and controls from prior and ongoing
clinical trials individually. All three cohorts supported the finding
of an approximate 20% reduction in α-syn transcripts even in
newly diagnosed PD patients (Locascio et al., 2015). However,
this finding could be interpreted as support of loss-of-function,
gain-of-function, or be unrelated to processes operating in brain.
Abundant information from human genetic studies document
a clear association between increases in α-syn gene-dosing, or
mutations, that exacerbate aggregation and lead to PD. In line
with our hypothesis, these all are processes that can directly
increase the sequestration of α-syn away from the synapse
via increased aggregation kinetics (e.g., enhanced molecular
crowding). Nevertheless, one would expect that if α-syn is
crucial for maintaining the viability of DA neurons, human
genetic data on risk of PD also would implicate mutations or
polymorphisms that result in decreased α-syn. Indeed, a recent
report has described exactly that (Markopoulou et al., 2014). The
dinucleotide repeat REP1 is positioned upstream of the SNCA
transcription start site. Polymorphisms at this site are associated
with either increased or decreased SNCA expression. Contrary to
the investigator’s hypothesis that polymorphisms associated with
decreased expression of α-synwould be associated with decreased
risk of PD, these low α-syn individuals exhibited increased
risk of developing PD as well as worse motor and cognitive
outcomes.
LOSS-OF-FUNCTION,
GAIN-OF-FUNCTION OR A BIT OF BOTH?
Loss-of-function and gain-of-function hypotheses are not
irreconcilable. The absence of an overt parkinsonian phenotype
and DA neuron degeneration in germline α-syn knockout mice
does not directly address the loss-of-function hypothesis. Whole
genome expression analysis of SNCA(−/−) mice identified
differential expression of 369 transcripts as compared to wild-
type animals (Kuhn et al., 2007). This includes increased
expression of transcripts of other synuclein family members,
14-3-3 proteins, TH and neurotrophic factors, decreased
expression of pro-apoptotic transcripts, and changes in genes
directly involved in vesicle function and neurotransmission.
Thus, the lack of a severe phenotype in these animals is likely
the result of complex germline compensation for α-syn function.
While heritable forms of PD associated with duplication and
triplication of the SNCA gene arguably support the toxic gain-
of-function hypothesis, germline α-syn overexpression mice do
not directly support this contention. The available mouse models
exhibit little or no degeneration of SN DA neurons, although
similar to α-syn knockout mice, show prominent changes in
striatal DA neurotransmission (e.g., Chesselet and Richter, 2011;
Crabtree and Zhang, 2012 for reviews). Nevertheless, if the α-syn
transgene is induced in the mature animal, nigral degeneration
does occur (Lin et al., 2012). Thus, it is plausible that germline
compensation, similar to that seen in the knockout, occurs in
overexpression transgenic models as well.
While germline transgenic models do little to inform the toxic
gain-of-function/loss-of-function debate it is inarguable that too
much α-syn and mutant α-syn can produce direct neurotoxicity.
In vitro studies demonstrate that specific conformations of α-
syn exert cytotoxic effects by permeabilizing vesicles, altering
calcium flux, impairing mitochondrial function, and inducing
apoptosis (Volles et al., 2001; Pieri et al., 2012; Luth et al.,
2014; Pacheco et al., 2015). In addition, viral vector-mediated
overexpression of α-syn in DA neurons uniformly produces
significant, albeit variable in magnitude, neurodegeneration (e.g.,
Van der Perren et al., 2014 for review). However, in this case
it is unclear what precipitates neurodegeneration. Nonetheless,
in line with our hypothesis, and with data gained from the PFF
model (i.e., Osterberg et al., 2015) it is plausible that loss of
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FIGURE 2 | Hypothesis: Alpha-synuclein loss-of-function as a contributor to parkinsonian pathology. Our findings suggest that the region-specific
degeneration of ventral midbrain dopamine neurons characteristic of Parkinson’s disease that is widely attributed to accumulation of toxic aggregates of
alpha-synuclein can be accurately reproduced by knockdown of endogenous alpha-synuclein. These differing paths to degeneration converge upon displacement of
alpha-synuclein from its natural location at synaptic terminals.
soluble endogenous α-syn to aggregation is one contributor to
neurotoxicity. Thus, experimental support for both viewpoints
suggests a “Goldilocks” biology commonly exhibited by many
molecules: too much is bad, too little is bad, enough is just right
(Kanaan and Manfredsson, 2012).
CONCLUSIONS
In this Hypothesis and Theory article we address the alpha-
synuclein gain-of-function vs. loss-of-function debate as it
applies to DA neuron pathology in PD. Our experimental
findings in rats and non-human primates, combined with
support for the concept from other reports in the literature, leads
to the proposal that loss-of-function plays a significant role in this
pathology. On its surface, the α-syn loss-of-function hypothesis
seems counterintuitive since α-syn accumulation as aggregates,
in the form of Lewy bodies, is a key neuropathologic feature of
PD. However, while experimental observations largely have been
interpreted as suggestive of a cytotoxic role for α-syn, it does
not preclude the alternate interpretation that α-syn aggregation
reflects processes that prevent α-syn from performing its normal
biological functions. Our recent findings in non-human primates
support the contention that α-syn loss-of-function in midbrain
DA neurons accurately reproduces the pattern of nigrostriatal
degeneration observed in PD, and that α-syn aggregation, acting
as a “sink,” is one possible driver of this process rather than a
direct toxic culprit in cell loss (Figure 2). The findings suggest
reconsideration of the relationship of α-syn to PD pathogenesis
and caution in the implementation of α-syn clearance therapeutic
strategies that do not distinguish between natural forms and
pathological forms.
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